Skip to main content

Day: June 17, 2020

RECORDATI: ISTURISA® (OSILODROSTAT) PHASE III LINC-4 TRIAL MEETS ITS PRIMARY ENDPOINT IN CUSHING’S DISEASE

RECORDATI: ISTURISA® (OSILODROSTAT) PHASE III LINC-4 TRIAL MEETS ITS PRIMARY ENDPOINT IN CUSHING’S DISEASEIsturisa® (osilodrostat) demonstrates significant and sustained benefit over placebo at normalizing mean urinary free cortisol (mUFC) levels in patients with Cushing’s diseaseMilan, 17 June 2020 – Recordati today announces positive results from the large Phase III LINC-4 study of Isturisa® (osilodrostat) for the treatment of patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative. Data from the LINC-4 study demonstrate that a significantly higher proportion of patients receiving Isturisa® achieve normal mUFC, the primary treatment goal for Cushing’s disease, after 12 weeks of treatment versus placebo (77% vs 8%; P

Continue reading

RECORDATI: ISTURISA® (OSILODROSTAT) STUDIO DI FASE III LINC-4 RAGGIUNGE L’ENDPOINT PRIMARIO NELLA MALATTIA DI CUSHING

RECORDATI: ISTURISA® (OSILODROSTAT) STUDIO DI FASE III LINC-4 RAGGIUNGE L’ENDPOINT PRIMARIO NELLA MALATTIA DI CUSHINGIsturisa® (osilodrostat) dimostra un significativo e sostenuto beneficio contro placebo nella normalizzazione dei livelli medi di cortisolo libero urinario in pazienti affetti dalla malattia di Cushing.Milano, 17 giugno 2020 – Recordati annuncia i risultati positivi del secondo studio registrativo di Fase III LINC-4 con Isturisa® (osilodrostat) nel trattamento di pazienti con malattia di Cushing per i quali l’intervento chirurgico all’’ipofisi non è indicato o non è stato risolutivo. I risultati dello studio LINC-4 dimostrano che una percentuale significativamente superiore di pazienti randomizzati al trattamento con Isturisa® rispetto a quelli randomizzati al trattamento con placebo (77% vs 8%; P

Continue reading

Ideanomics Receives a 300 Unit EV Order from Didi City

NEW YORK, Ideanomics (NASDAQ: IDEX) announced that its subsidiary Mobile Energy Global (MEG) has secured an order from Didi City CP, a licensed city operator of Didi Chuxing (DiDi). Didi is the world’s leading mobile transportation/ride-share platform, similar to Uber, and serves over 550 million users across Asia, Latin America, and Australia. The order is for a total of 300 electric vehicles (EVs) and valued at RMB 30 Million, or USD 4.2 Million. The order will be fulfilled with either Dongfeng E70 or Geely Emgrand EV 500 models and, subject to final negotiations with manufacturers, financing, government licensing, etc., delivery of EVs to Didi City CP is expected to commence later this month. About IdeanomicsIdeanomics is a global company focused on facilitating the adoption of commercial electric vehicles and developing next...

Continue reading

LIDDS publishes prospectus in connection with forthcoming rights issue

LIDDS AB (“LIDDS” or the “Company”) announced on 11 June 2020 that the Board of Directors, pursuant to the authorization granted by the annual general meeting, has resolved to carry out, inter alia, a new share issue with pre-emption rights for existing shareholders (the “Rights Issue”). The Board of Directors has prepared an EU Growth prospectus in connection with the Rights Issue (the “Prospectus”), which has been approved and registered by the Swedish Financial Supervisory Authority and subsequently published by the Company.Publication of the ProspectusLIDDS announces today that the Prospectus regarding the Rights Issue has been approved and registered by the Swedish Financial Supervisory Authority and is available on the Company’s website, www.liddspharma.com/share-issue-2020/, together with all other information related to the Rights...

Continue reading

LIDDS offentliggör prospekt med anledning av förestående företrädesemission

LIDDS AB (“LIDDS” eller “Bolaget”) offentliggjorde den 11 juni 2020 att styrelsen, med stöd av årsstämmans bemyndigande, beslutat att bland annat genomföra en nyemission med företrädesrätt för befintliga aktieägare (“Företrädesemissionen”). Styrelsen har med anledning av Företrädesemissionen upprättat ett EU-tillväxtprospekt (”Prospektet”) som har godkänts och registrerats av Finansinspektionen samt därefter offentliggjorts av Bolaget.Offentliggörande av ProspektLIDDS meddelar idag att Prospektet avseende Företrädesemissionen har godkänts och registrerats av Finansinspektionen och finns tillgängligt på Bolagets hemsida, www.liddspharma.com/share-issue-2020/, tillsammans med all annan information relaterad till Företrädesemissionen. Prospektet kommer även göras tillgängligt på Finansinspektionens hemsida,...

Continue reading

Groupe Renault : mise à disposition des ventes de mai 2020

Communiqué de mise à disposition – Ventes de mai 2020Boulogne, le 17 juin 2020Renault annonce la mise à disposition de son rapport des ventes de mai 2020 sur le site Internet de la Société à l’adresse www.group.renault.com, dans la rubrique « Finance », puis « Informations réglementées », « ventes mensuelles ».Pièce jointeMise à disposition Ventes RENAULT

Continue reading

Vistin Pharma ASA: Guide for online participation at EGM

Oslo, Norway, 17 June 2020Vistin Pharma ASA (OSE: VISTIN), as previously announced Vistin Pharma ASA will be conducting the Extraordinary General Meeting on the 24 of June as a digital meeting, through Skype. This is a precautionary measure to prevent the spread of Covid-19 and to ensure the safety and wellbeing of our shareholders, employees and other stakeholders. Therefore, there will be no opportunity for physical presence. You may cast votes prior to the meeting or grant a proxy. Please refer the notice for the EGM and appendices for further information on voting in advance and proxies. Attached is a stepwise guide for how to attend the meeting.The complete set of documents relating to the Extraordinary General Meeting are available on www.vistin.com.For further information, please contact:Alexander KarlsenCFO+47 97 05 36 21alexander.karlsen@vistin.comThis...

Continue reading

QuestCap Provides Corporate Update on Recent Investments in Sunnybrook Hospital, Mount Sinai Hospital, and Antibody Test Kit Distribution

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESTORONTO, June 17, 2020 (GLOBE NEWSWIRE) — Social-impact investment company QuestCap Inc. (CSE:QSC; FRA:34C1) is pleased to provide a corporate update and provide developments from investment partners.QuestCap’s recent investments and partnerships include:Sunnybrook Hospital’s Research Group for Emerging and Respiratory Viruses, founding investment has allowed Sunnybrook to accelerate their work on potential vaccines and treatments for COVID-19Mount Sinai Hospital, QuestCap has funded research in to an automated, high-throughput serosurveillance platformMTJR, profit-sharing agreement with distributor MTJR, who has entered into an agreement to secure the exclusive right to distribute and market PCL’s COVID19 Rapid IgG/IgM Gold Tests in...

Continue reading

TGS Announces 2Dcubed Seismic Project to Cover License Round Acreage Offshore Timor-Leste

Asker, Norway (17 June 2020) – TGS, a leading provider of multi-client geoscience data for exploration & production (E&P) companies, today announced that in collaboration with the ANPM, it has commenced a 2Dcubed  seismic data project covering offshore Timor-Leste, in support of the country’s ongoing license round.The project combines all available open file and TGS multi-client data across an area of over 50,000 square kilometers and incorporating over 2,500 lines and existing 3D’s within the planned area. The 2D data, from over 45 legacy vintages, covers the entire offshore area south of Timor-Leste where the 11 offshore blocks in the second license round are located.The final multi-client 2Dcubed data will be unrivalled in its comprehensive coverage, allowing customers to develop structural and geological models in their...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.